Dataset.

Data from "Relationship between weight and dimensions of Bluefin tuna (Thunnus thynnus) following fattening on western Mediterranean farms"

Digital.CSIC. Repositorio Institucional del CSIC
oai:digital.csic.es:10261/312535
Digital.CSIC. Repositorio Institucional del CSIC
  • Puig, V.
  • Estruch, Vicente Domingo
  • Espinosa, Víctor
  • de-la-Gándara, Fernando
  • Mèlich, B.
  • Cort, José Luis
 
DOI: http://hdl.handle.net/10261/312535
Digital.CSIC. Repositorio Institucional del CSIC
oai:digital.csic.es:10261/312535

HANDLE: http://hdl.handle.net/10261/312535
Digital.CSIC. Repositorio Institucional del CSIC
oai:digital.csic.es:10261/312535
 
Ver en: http://hdl.handle.net/10261/312535
Digital.CSIC. Repositorio Institucional del CSIC
oai:digital.csic.es:10261/312535

Recercat. Dipósit de la Recerca de Catalunya
oai:recercat.cat:2072/315385
Artículo científico (article).

DOES PET OWNERSHIP IN INFANCY LEAD TO ASTHMA OR ALLERGY AT SCHOOL AGE? POOLED ANALYSIS OF INDIVIDUAL PARTICIPANT DATA FROM 11 EUROPEAN BIRTH COHORTS

Recercat. Dipósit de la Recerca de Catalunya
  • Lodrup Carlsen, Karin C
  • Sunyer Deu, Jordi
  • Puig, Carme
  • Wickman, Magnus
Objective: To examine the associations between pet keeping in early childhood and asthma and allergies in children aged 6–10 years. Design: Pooled analysis of individual participant data of 11 prospective European birth cohorts that recruited a total of over 22,000 children in the 1990s. Exposure definition: Ownership of only cats, dogs, birds, rodents, or cats/dogs combined during the first 2 years of life. Outcome definition: Current asthma (primary outcome), allergic asthma, allergic rhinitis and allergic sensitization during 6–10 years of age. Data synthesis: Three-step approach: (i) Common definition of outcome and exposure variables across cohorts; (ii) calculation of adjusted effect estimates for each cohort; (iii) pooling of effect estimates by using random effects meta-analysis models.Results: We found no association between furry and feathered pet keeping early in life and asthma in school age. For example, the odds ratio for asthma comparing cat ownership with “no pets” (10 studies, 11489 participants) was 1.00 (95% confidence interval 0.78 to 1.28) (I2 = 9%; p = 0.36). The odds ratio for asthma comparing dog ownership with “no pets” (9 studies, 11433 participants) was 0.77 (0.58 to 1.03) (I2 = 0%, p = 0.89). Owning both cat(s) and dog(s) compared to “no pets” resulted in an odds ratio of 1.04 (0.59 to 1.84) (I2 = 33%, p = 0.18). Similarly, for allergic asthma and for allergic rhinitis we did not find associations regarding any type of pet ownership early in life. However, we found some evidence for an association between ownership of furry pets during the first 2 years of life and reduced likelihood of becoming sensitized to aero-allergens. Conclusions: Pet ownership in early life did not appear to either increase or reduce the risk of asthma or allergic rhinitis symptoms in children aged 6–10. Advice from health care practitioners to avoid or to specifically acquire pets for primary prevention of asthma or allergic rhinitis in children should not be given., This collaborative project was initiated, supported and funded by the Global Allergy and Asthma European Network (GA2LEN; www.ga2len.net) under the 6th framework programme of the European Commission (project no. FOOD-CT-2004-506378). Sources of funding of the individual birth cohort studies are described in their publications




r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p13445
Otros (other). 2020

EFFICACY AND SAFETY OF BARICITINIB AND TOFACITINIB IN RHEUMATOID ARTHRITIS: DATA FROM REAL-WORLD

r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
  • Mazario, RG
  • Fragio-Gil, J. J.
  • Garcia, EG
  • Navarro, MD
  • Perales, CP
  • Rodriguez, SL
  • Cortes, JI
  • Albuixech, RN
  • Puig, LG
  • Rodriguez, JEO
  • Escandell, CA
  • Bernabeu, EV
  • Verdejo, IC
  • Cordellat, IM
  • Sanjuan, FMO
  • Herranz, CN
  • Olmos, IC
  • Martinez, AJC
  • Ivorra, JAR



r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
oai:fundanet.iislafe.san.gva.es:p20528
Artículo científico (article). 2024

EFFECTIVENESS AND TOLERABILITY OF BRIVARACETAM IN PATIENTS WITH EPILEPSY STRATIFIED BY COMORBIDITIES AND ETIOLOGY IN THE REAL WORLD: 12-MONTH SUBGROUP DATA FROM THE INTERNATIONAL EXPERIENCE POOLED ANALYSIS.

r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
  • Szaflarski, Jerzy P
  • Besson, Herve
  • D'Souza, Wendyl
  • Faught, Edward
  • Klein, Pavel
  • Reuber, Markus
  • Rosenow, Felix
  • Salas-Puig, Javier
  • Soto Insuga, Victor
  • Steinhoff, Bernhard J
  • Strzelczyk, Adam
  • Bourikas, Dimitrios
  • Daniels, Tony
  • Floricel, Florin
  • Friesen, David
  • Laloyaux, Cedric
  • Villanueva, Vicente
OBJECTIVE: To assess the effectiveness and tolerability of brivaracetam (BRV) in adults with epilepsy by specific comorbidities and epilepsy etiologies. METHODS: EXPERIENCE/EPD332 was a pooled analysis of individual patient records from several non-interventional studies of patients with epilepsy initiating BRV in clinical practice. Outcomes included=50% reduction from baseline in seizure frequency, seizure freedom (no seizures within prior 3months), continuous seizure freedom (no seizures since baseline), BRV discontinuation, and treatment-emergent adverse events (TEAEs) at 3, 6, and 12months. Analyses were performed for all adult patients (=16years of age) and stratified by comorbidity and by etiology at baseline (patients with cognitive/learning disability [CLD], psychiatric comorbidity, post-stroke epilepsy, brain tumor-related epilepsy [BTRE], and traumatic brain injury-related epilepsy [TBIE]). RESULTS: At 12months,=50% seizure reduction was achieved in 35.6% (n=264), 38.7% (n=310), 41.7% (n=24), 34.1% (n=41), and 50.0% (n=28) of patients with CLD, psychiatric comorbidity, post-stroke epilepsy, BTRE, and TBIE, respectively; and continuous seizure freedom was achieved in 5.7% (n=318), 13.7% (n=424), 29.4% (n=34), 11.4% (n=44), and 13.8% (n=29), respectively. During the study follow-up, in patients with CLD, psychiatric comorbidity, post-stroke epilepsy, BTRE, and TBIE, 37.1% (n=403), 30.7% (n=605), 33.3% (n=51), 39.7% (n=68), and 27.1% (n=49) of patients discontinued BRV, respectively; and TEAEs since prior visit at 12months were reported in 11.3% (n=283), 10.0% (n=410), 16.7% (n=36), 12.5% (n=48), and 3.0% (n=33), respectively. CONCLUSIONS: BRV as prescribed in the real world is effective and well tolerated among patients with CLD, psychiatric comorbidity, post-stroke epilepsy, BTRE, and TBIE.



r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
oai:iibsantpau.fundanetsuite.com:p1487
Artículo científico (article). 2020

DUPILUMAB IMPROVES PATIENT-REPORTED SYMPTOMS OF ATOPIC DERMATITIS, SYMPTOMS OF ANXIETY AND DEPRESSION, AND HEALTH-RELATED QUALITY OF LIFE IN MODERATE-TO-SEVERE ATOPIC DERMATITIS: ANALYSIS OF POOLED DATA FROM THE RANDOMIZED TRIALS SOLO 1 AND SOLO 2

r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
  • Cork, MJ
  • Eckert, L
  • Simpson, EL
  • Armstrong, A
  • Barbarot, S
  • Puig, L
  • Girolomoni, G
  • de Bruin-Weller, M
  • Wollenberg, A
  • Kataoka, Y
  • Remitz, A
  • Beissert, S
  • Mastey, V
  • Ardeleanu, M
  • Chen, Z
  • Gadkari, A
  • Chao, JD
Background: Atopic dermatitis (AD) profoundly affects quality of life (QoL). Dupilumab significantly improves clinical outcomes, is well tolerated, and approved to treat inadequately controlled moderate-to-severe AD in adults; however, its effect on patient-reported outcomes (PROs) is not fully characterized. Objective: To evaluate the impact of dupilumab on patient-reported AD symptoms and QoL. Methods: Pooled data were analyzed from two identically designed phase 3 studies, LIBERTY AD SOLO 1 (NCT02277743) and SOLO 2 (NCT02277769), assessing the following PROs: Peak Pruritus Numerical Rating Scale (NRS), Pruritus Categorical Scale, SCORing AD (SCORAD), Dermatology Life Quality Index (DLQI), Patient-Oriented Eczema Measure (POEM), Hospital Anxiety and Depression Scale (HADS), five-dimension EuroQoL questionnaire (EQ-5D), and patient-assessed disease status and treatment effectiveness. Results: Dupilumab rapidly improved (vs. placebo) Peak Pruritus NRS scores by day 2 (p < .05), anxiety and depression (HADS), and QoL (DLQI) by week 2, and maintained through week 16 (p < .0001). At week 16, more dupilumab-treated than placebo-treated patients reported improvement in SCORAD itch and sleep, and no pain/discomfort (EQ-5D) (p < .0001). Limitations: Cultural differences of translated PROs. Conclusion: Dupilumab had a significant, positive impact on AD symptoms, including itch, sleep, pain, anxiety and depression, and QoL in adults with moderate-to-severe AD.



r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
oai:iibsantpau.fundanetsuite.com:p2314
Otros (other). 2020

INCIDENCE OF CARDIOVASCULAR EVENTS AMONG TILDRAKIZUMAB-TREATED PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS: POOLED DATA FROM THREE LARGE RANDOMISED CLINICAL TRIALS

r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
  • Bissonnette, R
  • Fernandez-Penas, P
  • Puig, L
  • Mendelsohn, AM
  • Rozzo, SJ
  • Menter, A



r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
oai:iibsantpau.fundanetsuite.com:p3010
Artículo científico (article). 2019

REVERSIBILITY OF ALEXITHYMIA WITH EFFECTIVE TREATMENT OF MODERATE-TO-SEVERE PSORIASIS: LONGITUDINAL DATA FROM EPIDEPSO

r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
  • Sampogna, F
  • Puig, L
  • Spuls, P
  • Girolomoni, G
  • Radtke, MA
  • Kirby, B
  • Brunori, M
  • Bergmans, P
  • Smirnov, P
  • Rundle, J
  • Castiglia, A
  • Lavie, F
  • Paul, C
Background Alexithymia refers to difficulty in identifying and expressing emotions. Alexithymia is associated with high burden of disease in patients with psoriasis. Objectives To investigate whether alexithymia was reversible in patients with psoriasis following real-life therapeutic intervention. Methods The Epidemiological Study in Patients with Recently Diagnosed Psoriasis (EPIDEPSO; NCT01964443) was a 1-year multicentre observational study investigating the prevalence of alexithymia and other psychosocial comorbidities in patients with psoriasis with <= 10 years' disease duration and eligible for systemic treatment. Alexithymia was assessed using the Toronto Alexithymia Scale (TAS-20) at baseline, 6 months and 1 year. Results There was a statistically significant decrease in the prevalence of alexithymia in the follow-up cohort, from 26 center dot 7% at baseline to 21 center dot 2% at 6 months and 18 center dot 8% at 1 year. More than half of the patients (n = 77, 53 center dot 8%) who were alexithymic at baseline experienced reversion of their alexithymia. Reversion of alexithymia was higher in patients who reached a high level of disease control, defined as >= 75% or >= 90% improvement in Psoriasis Area and Severity Index. Reversion of alexithymia was associated with dramatic improvement in quality of life, anxiety and depression. Moreover, hazardous alcohol use, highly prevalent in patients with alexithymia, was reduced almost threefold at 1 year. Conclusions Alexithymia and associated high disease burden may be reversible in patients with effective treatment of psoriasis. Proactive recognition of patients who are unable to identify and express their feelings is important.



r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
oai:iibsantpau.fundanetsuite.com:p7277
Artículo científico (article). 2016

ONE-YEAR REFERENCE NORMS OF COGNITIVE CHANGE IN SPANISH OLD ADULTS: DATA FROM THE NEURONORMA SAMPLE

r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
  • Sanchez-Benavides, G
  • Pena-Casanova, J
  • Casals-Coll, M
  • Gramunt, N
  • Manero, RM
  • Puig-Pijoan, A
  • Aguilar, M
  • Robles, A
  • Antunez, C
  • Frank-Garcia, A
  • Fernandez-Martinez, M
  • Blesa, R
Objective. Serial cognitive assessments are useful for many purposes, such as monitoring cognitive decline or evaluating the result of an intervention. In order to determine if an observed change is reliable and meaningful, longitudinal reference data from non-clinical samples are needed. Since neuropsychological outcomes are affected by language and cultural background, cognitive tests should be adapted, and country-based norms collected. The lack of cross-sectional normative data for Spanish population has been partially remediated, but there is still a need of reliable change norms. This paper aims to give an initial response to this need by providing several reliable change indices (RCI) for 1-year follow-up in a Spanish sample. Method. A longitudinal observational study was designed. A total of 122 healthy subjects over age 50 were evaluated twice (M = 369.5, SD= 10.7 days) with the NEURONORMA battery. Scores changes were analyzed, and simple discrepancy scores, standard deviation indices, RCI, and standardized regression-based scores were calculated. Results. Significant improvements were observed in variables related to memory, both verbal and visual, visuospatial function, and the completion time of complex problems. Reference tables for several RCI are provided for their use in clinical settings. Conclusions. Our results confirm the existence of heterogeneous practice effects after 1 year, and support the recommendation of using reliable change norms to avoid misdiagnosis in repeated assessments. This study provides with initial, preliminary norms of cognitive change for its use in Spanish elders. Further studies on larger samples and different inter-visit intervals are still needed.



r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
oai:iibsantpau.fundanetsuite.com:p9273
Artículo científico (article). 2014

USTEKINUMAB, AN ANTI-IL-12/23 P40 MONOCLONAL ANTIBODY, INHIBITS RADIOGRAPHIC PROGRESSION IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS OF AN INTEGRATED ANALYSIS OF RADIOGRAPHIC DATA FROM THE PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PSUMMIT-1 AND PSUMMIT-2 TRIALS

r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
  • Kavanaugh, A
  • Ritchlin, C
  • Rahman, P
  • Puig, L
  • Gottlieb, AB
  • Li, S
  • Wang, YH
  • Noonan, L
  • Brodmerkel, C
  • Song, M
  • Mendelsohn, AM
  • McInnes, IB
Objective Evaluate ustekinumab, an anti-interleukin (IL)-12 and IL-23 antibody, effects on radiographic progression in psoriatic arthritis (PsA). Methods We conducted preplanned integrated analyses of combined radiographic data from PSUMMIT-1 and PSUMMIT-2 phase 3, randomised, controlled trials. Patients had active PsA despite prior conventional and/or biologic disease-modifying antirheumatic drugs (>= 5/66 swollen, >= 5/68 tender joints, C-reactive protein >= 3.0 mg/L, documented plaque psoriasis). Patients (PSUMMIT-1, n=615; PSUMMIT-2, n=312) were randomised to ustekinumab 45 mg, 90 mg, or placebo, at weeks (wk) 0, 4 and every (q) 12 wks. At wk 16, patients with <5% improvement in tender/swollen joint counts entered blinded early escape. All other placebo patients received ustekinumab 45 mg at wk 24 and wk 28, then q 12 wks. Radiographs of hands/feet at wks 0/24/52 were assessed using PsA-modified van der Heijde-Sharp (vdH-S) scores; combined PSUMMIT-1 and PSUMMIT-2 changes in total vdH-S scores from wk 0 to wk 24 comprised the prespecified primary radiographic analysis. Treatment effects were assessed using analysis of variance on van der Waerden normal scores (factors=treatment, baseline methotrexate usage, and study). Results Integrated data analysis results indicated that ustekinumab-treated patients (regardless of dose) demonstrated significantly less radiographic progression at wk 24 than did placebo recipients (wk 0-24 total vdH-S score mean changes: 0.4-combined/individual ustekinumab dose groups, 1.0-placebo; all p<0.02). From wk 24 to wk 52, inhibition of radiographic progression was maintained for ustekinumab-treated patients, and progression was substantially reduced among initial placebo recipients who started ustekinumab at wk 16 or wk 24 (wk 24 - wk 52, total vdH-S score mean change: 0.08). Conclusions Ustekinumab 45 and 90 mg treatments significantly inhibited radiographic progression of joint damage in patients with active PsA.



r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
oai:iibsantpau.fundanetsuite.com:p14914
Artículo científico (article). 2022

PREVALENCE AND RISK FACTORS OF DIABETIC FOOT DISEASE AMONG THE PEOPLE WITH TYPE 2 DIABETES USING REAL-WORLD PRACTICE DATA FROM CATALONIA DURING 2018

r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
  • Bundo, M
  • Vlacho, B
  • Llussa, J
  • Puig-Treserra, R
  • Mata-Cases, M
  • Cos, X
  • Jude, EB
  • Franch-Nadal, J
  • Mauricio, D
BackgroundOur study aimed to assess the prevalence of diabetic foot disease (DFD) and its associated risk factors among subjects attending primary care centers in Catalonia (Spain). MethodsWe undertook a cross-sectional analysis of data from the primary health care (SIDIAP) database. The presence of comorbidities and concomitant medication were analyzed for subjects with or without DFD. DFD prevalence was estimated from 1st January 2018 to 31st December 2018. ResultsDuring the 12-month observational period, out of 394,266 people with type 2 diabetes, we identified 3,277 (0.83%) active episodes of DFD in the database. The majority of these episodes were foot ulcers (82%). The mean age of patients with DFD was 70.3 (+/- 12.5) years and 55% were male. In the multivariable descriptive models, male gender, diabetes duration, hypertension, macrovascular, microvascular complications, and insulin and antiplatelet agents were strongly associated with DFD. A previous history of DFD was the stronger risk factor for DFD occurrence in subjects with T2DM (OR: 13.19, 95%CI: 11.81; 14.72). ConclusionsIn this real-world primary care practice database, we found a lower prevalence of DFD compared to similar previous studies. Risk factors such as male sex, duration of diabetes, diabetes complications and previous history of DFD were associated with the presence of DFD.



Dipòsit Digital de Documents de la UAB
oai:ddd.uab.cat:277674
Artículo científico (article). 2022

PREVALENCE AND RISK FACTORS OF DIABETIC FOOT DISEASE AMONG THE PEOPLE WITH TYPE 2 DIABETES USING REAL-WORLD PRACTICE DATA FROM CATALONIA DURING 2018

Dipòsit Digital de Documents de la UAB
  • Bundó, Magdalena
  • Vlacho, Bogdan|||0000-0003-3768-8112
  • Llussà, Judith|||0000-0002-6886-6084
  • Puig Treserra, Ramon|||0000-0003-1224-884X
  • Mata-Cases, M.
  • Cos, Xavier
  • Jude, E.B.
  • Franch-Nadal, J.
  • Mauricio Puente, Dídac|||0000-0002-2868-0250
Background: Our study aimed to assess the prevalence of diabetic foot disease (DFD) and its associated risk factors among subjects attending primary care centers in Catalonia (Spain). Methods: We undertook a cross-sectional analysis of data from the primary health care (SIDIAP) database. The presence of comorbidities and concomitant medication were analyzed for subjects with or without DFD. DFD prevalence was estimated from 1st January 2018 to 31st December 2018. Results: During the 12-month observational period, out of 394,266 people with type 2 diabetes, we identified 3,277 (0.83%) active episodes of DFD in the database. The majority of these episodes were foot ulcers (82%). The mean age of patients with DFD was 70.3 (± 12.5) years and 55% were male. In the multivariable descriptive models, male gender, diabetes duration, hypertension, macrovascular, microvascular complications, and insulin and antiplatelet agents were strongly associated with DFD. A previous history of DFD was the stronger risk factor for DFD occurrence in subjects with T2DM (OR: 13.19, 95%CI: 11.81; 14.72). Conclusions: In this real-world primary care practice database, we found a lower prevalence of DFD compared to similar previous studies. Risk factors such as male sex, duration of diabetes, diabetes complications and previous history of DFD were associated with the presence of DFD.




Digital.CSIC. Repositorio Institucional del CSIC
oai:digital.csic.es:10261/269620
Dataset. 2017

DATA FROM: ANALYSIS OF THE PORCINE APOA2 GENE EXPRESSION IN LIVER, POLYMORPHISMS IDENTIFICATION AND ASSOCIATION WITH FATTY ACID COMPOSITION TRAITS

Digital.CSIC. Repositorio Institucional del CSIC
  • Ballester, María
  • Revilla, Manuel
  • Puig-Oliveras, Anna
  • Marchesi, J.A.P.
  • Castelló, Anna
  • Corominas, Jordi
  • Fernández, Ana Isabel
  • Folch, Josep María
Usage Notes Porcine APOA2 gene expression in liver Data from Analysis of the porcine APOA2 gene expression in liver, polymorphisms identification and association with fatty acid composition traits. Contains SNP genotypes for GWAS and eGWAS studies, mRNA expression of APOA2 in liver, and fatty acid composition in backfat and muscle, APOA2 is a protein implicated in triglyceride, fatty acid and glucose metabolism. In pigs, the APOA2 gene is located on pig chromosome 4 (SSC4) in a QTL region affecting fatty acid composition, fatness and growth traits. In this study, we evaluated APOA2 as a candidate gene for meat quality traits in an Iberian × Landrace backcross population. The APOA2:c.131T>A polymorphism, located in exon 3 of APOA2 and determining a missense mutation, was associated with the percentage of hexadecenoic acid [C16:1(n–9)], linoleic acid [C18:2(n–6)], α-linolenic acid [C18:3(n–3)], dihomo-gamma-linolenic acid [C20:3(n–6)] and polyunsaturated fatty acids (PUFAs) in backfat. Furthermore, this SNP was associated with the global mRNA expression levels of APOA2 in liver and was used as a marker to determine allelic expression imbalance by pyrosequencing. We determined an overexpression of the T allele in heterozygous samples with a mean ratio of 2.8 (T/A), observing a high variability in the allelic expression among individuals. This result suggests that complex regulatory mechanisms, beyond a single polymorphism (e.g. epigenetic effects or multiple cis-acting polymorphisms), may be regulating APOA2 gene expression., Peer reviewed




Digital.CSIC. Repositorio Institucional del CSIC
oai:digital.csic.es:10261/312535
Dataset. 2017

DATA FROM &QUOT;RELATIONSHIP BETWEEN WEIGHT AND DIMENSIONS OF BLUEFIN TUNA (THUNNUS THYNNUS) FOLLOWING FATTENING ON WESTERN MEDITERRANEAN FARMS&QUOT;

Digital.CSIC. Repositorio Institucional del CSIC
  • Puig, V.
  • Estruch, Vicente Domingo
  • Espinosa, Víctor
  • de-la-Gándara, Fernando
  • Mèlich, B.
  • Cort, José Luis




1106